Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 10
1979 1
1980 2
1981 3
1982 6
1983 3
1984 1
1985 3
1986 1
1987 9
1988 12
1989 14
1990 24
1991 16
1992 19
1993 22
1994 16
1995 27
1996 19
1997 18
1998 13
1999 17
2000 9
2001 18
2002 18
2003 14
2004 11
2005 13
2006 11
2007 6
2008 9
2009 6
2010 6
2011 7
2012 6
2013 3
2014 2
2015 5
2016 1
2017 3
2018 2
2019 1
2020 4
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

400 results
Results by year
Filters applied: . Clear all
Page 1
Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia.
Wiklund O, Angelin B, Bergman M, Berglund L, Bondjers G, Carlsson A, Lindén T, Miettinen T, Odman B, Olofsson SO, et al. Wiklund O, et al. Am J Med. 1993 Jan;94(1):13-20. doi: 10.1016/0002-9343(93)90114-5. Am J Med. 1993. PMID: 8420296 Clinical Trial.
PURPOSE: To compare the efficacy and safety of pravastatin, gemfibrozil, combined therapy, and placebo in the treatment of hypercholesterolemia. ...Pravastatin and gemfibrozil increased apolipoprotein A-I comparably (3.3% versus 5.0%, p = NS). ...
PURPOSE: To compare the efficacy and safety of pravastatin, gemfibrozil, combined therapy, and placebo in the treatment of hyperchole …
Hyperlipoproteinemia, atherosclerosis and gemfibrozil.
Nash DT. Nash DT. Angiology. 1982 Sep;33(9):594-602. doi: 10.1177/000331978203300905. Angiology. 1982. PMID: 6957155 Clinical Trial.
A short term study using 1200 mg of gemfibrozil daily demonstrated reduction in total serum cholesterol, triglyceride and apo B levels, and a concomitant rise in HDL cholesterol levels. ...A recent study from New Zealand demonstrated that gemfibrozil, compared to pl …
A short term study using 1200 mg of gemfibrozil daily demonstrated reduction in total serum cholesterol, triglyceride and apo B level …
Comparison of gemfibrozil and clofibrate on serum lipids in familial combined hyperlipidemia. A randomized placebo-controlled, double-blind, crossover clinical trial.
Rabkin SW, Hayden M, Frohlich J. Rabkin SW, et al. Atherosclerosis. 1988 Oct;73(2-3):233-40. doi: 10.1016/0021-9150(88)90046-9. Atherosclerosis. 1988. PMID: 3056431 Clinical Trial.
A randomized double blind, placebo-controlled crossover design was used to determine the efficacy of gemfibrozil and clofibrate in the treatment of familial combined hyperlipidemia and to determine which one of these agents would be more effective. ...Patients received 6 w …
A randomized double blind, placebo-controlled crossover design was used to determine the efficacy of gemfibrozil and clofibrate in th …
Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man.
Kesäniemi YA, Grundy SM. Kesäniemi YA, et al. JAMA. 1984 May 4;251(17):2241-6. doi: 10.1001/jama.1984.03340410049031. JAMA. 1984. PMID: 6368883 Clinical Trial.
Mechanisms for the hypolipidemic action of gemfibrozil were examined in seven patients with hypertriglyceridemia. ...The first month was a control period, followed by one month of either gemfibrozil or clofibrate therapy. During treatment with gemfibrozil, pl …
Mechanisms for the hypolipidemic action of gemfibrozil were examined in seven patients with hypertriglyceridemia. ...The first month …
Lipoproteins and coronary heart disease in the Helsinki Heart Study.
Mänttäri M, Huttunen JK, Koskinen P, Manninen V, Tenkanen L, Heinonen OP, Frick MH. Mänttäri M, et al. Eur Heart J. 1990 Dec;11 Suppl H:26-31. doi: 10.1093/eurheartj/11.suppl_h.26. Eur Heart J. 1990. PMID: 2073911 Review.
Ultracentrifuge analysis in a subsample of the cohort revealed that gemfibrozil raised the level of HDL3-cholesterol but had little effect on HDL2-cholesterol. The gemfibrozil-associated reduction in the incidence of definite coronary events varied according to lipi …
Ultracentrifuge analysis in a subsample of the cohort revealed that gemfibrozil raised the level of HDL3-cholesterol but had little e …
Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia.
Wägner AM, Jorba O, Bonet R, Ordóñez-Llanos J, Pérez A. Wägner AM, et al. J Clin Endocrinol Metab. 2003 Jul;88(7):3212-7. doi: 10.1210/jc.2003-030153. J Clin Endocrinol Metab. 2003. PMID: 12843167 Clinical Trial.
To compare the effects of atorvastatin, gemfibrozil, and their combination on the components of diabetic dyslipidemia, 44 type 2 diabetic patients with low density lipoprotein cholesterol (LDLc) levels greater than 100 mg/dl and triglyceride levels less than 400 mg/dl were …
To compare the effects of atorvastatin, gemfibrozil, and their combination on the components of diabetic dyslipidemia, 44 type 2 diab …
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ. Jaakkola T, et al. Clin Pharmacol Ther. 2005 May;77(5):404-14. doi: 10.1016/j.clpt.2004.12.266. Clin Pharmacol Ther. 2005. PMID: 15900286 Clinical Trial.
METHODS: In a randomized, double-blind, 4-phase crossover study, 12 healthy volunteers took either 600 mg gemfibrozil or 100 mg itraconazole (first dose, 200 mg), both gemfibrozil and itraconazole, or placebo twice daily for 4 days. ...However, studies in diabetic p …
METHODS: In a randomized, double-blind, 4-phase crossover study, 12 healthy volunteers took either 600 mg gemfibrozil or 100 mg itrac …
Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.
Niemi M, Backman JT, Juntti-Patinen L, Neuvonen M, Neuvonen PJ. Niemi M, et al. Br J Clin Pharmacol. 2005 Aug;60(2):208-17. doi: 10.1111/j.1365-2125.2005.02385.x. Br J Clin Pharmacol. 2005. PMID: 16042675 Free PMC article. Clinical Trial.
In vitro, gemfibrozil is a more potent inhibitor of CYP2C9 than of CYP2C8. Our aim was to investigate the effects of the gemfibrozil-itraconazole combination on the pharmacokinetics and pharmacodynamics of another meglitinide analogue, nateglinide, which is metaboli …
In vitro, gemfibrozil is a more potent inhibitor of CYP2C9 than of CYP2C8. Our aim was to investigate the effects of the gemfibroz …
Gemfibrozil, lipids, and coronary risk.
Rifkind BM. Rifkind BM. N Engl J Med. 1987 Nov 12;317(20):1279-81. doi: 10.1056/NEJM198711123172008. N Engl J Med. 1987. PMID: 3313042 Clinical Trial. No abstract available.
Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses.
Honkalammi J, Niemi M, Neuvonen PJ, Backman JT. Honkalammi J, et al. Drug Metab Dispos. 2011 Oct;39(10):1977-86. doi: 10.1124/dmd.111.040931. Epub 2011 Jul 21. Drug Metab Dispos. 2011. PMID: 21778352 Clinical Trial.
Gemfibrozil 1-O-beta-glucuronide inactivates CYP2C8 irreversibly. We investigated the effect of gemfibrozil dose on CYP2C8 activity in humans using repaglinide as a probe drug. ...Gemfibrozil pharmacokinetics was characterized by a slightly more than dose-pro …
Gemfibrozil 1-O-beta-glucuronide inactivates CYP2C8 irreversibly. We investigated the effect of gemfibrozil dose on CYP2C8 act …
400 results